



OvaScience to Present at Upcoming Investor Conferences in March

February 27, 2017

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 27, 2017-- OvaScience? (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Christophe Couturier, Chief Financial Officer of OvaScience, will present a corporate overview at two upcoming conferences:

- **Cowen and Company 37th Annual Health Care Conference**

Date: Monday, March 6, 2017

Time: 2:00 p.m. ET

Location: Boston, MA

- **Oppenheimer 27th Annual Healthcare Conference**

Date: Tuesday, March 21, 2017

Time: 3:55 p.m. ET

Location: New York, NY

Live audio webcasts of the presentations can be accessed by visiting the investor section of the company's website at www.ovascience.com. A replay of the webcasts will be archived on the OvaScience website for 30 days following the presentations.

About OvaScience

OvaScience, Inc. (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because it believes women deserve more options. Each OvaScience treatment is based on the Company's proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC?) cells – immature egg cells found inside the protective ovarian lining. OvaScience is developing the OvaPrime? treatment, which could increase a woman's egg reserve, and the OvaTure? treatment, a potential next-generation in vitro fertilization (IVF) treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience's AUGMENT? treatment, a fertility option designed to improve IVF success rates, is available in certain IVF clinics in select international regions. OvaScience treatments are not available in the U.S. For more information, visit www.ovascience.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170227006342/en/>

Source: OvaScience

Media and Investor Contact:

OvaScience

Jennifer Viera, 617-420-8748

jviera@ovascience.com